BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.
|HQ||Palo Alto, CA, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (4-Jun-2021)
Closing stock price (4-Jun-2021)
|Company Name||Date||Deal Size|
|Adrenas Therapeutics, Inc.|
|Aspa Therapeutics, Inc.|
|BridgeBio Services, Inc.|
|Calcilytix Therapeutics, Inc.|
|CoA Therapeutics, Inc.|
|Dermecular Therapeutics, Inc.|
|Eidos Therapeutics, Inc.|
|Ferro Therapeutics, Inc.|
|Fortify Therapeutics, Inc.|
|Molecular Skin Therapeutics, Inc.|
When was BridgeBio founded?
BridgeBio was founded in 2014.
Who are BridgeBio key executives?
BridgeBio's key executives are Neil Kumar, Charles Homcy and Uma Sinha.
How many employees does BridgeBio have?
BridgeBio has 248 employees.
What is BridgeBio revenue?
Latest BridgeBio annual revenue is $8.2 m.
What is BridgeBio revenue per employee?
Latest BridgeBio revenue per employee is $33.3 k.
Who are BridgeBio competitors?
Competitors of BridgeBio include Hartington Pharmaceutical, Biogenes and Terns Pharmaceuticals.
Where is BridgeBio headquarters?
BridgeBio headquarters is located at 421 Kipling St, Palo Alto.
Where are BridgeBio offices?
BridgeBio has an office in Palo Alto.
How many offices does BridgeBio have?
BridgeBio has 1 office.
Receive alerts for 300+ data fields across thousands of companies